Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC)

被引：22
|
作者：
Janne, Pasi A.
Ramalingam, Suresh S.
Yang, James Chih-Hsin
Ahn, Myung-Ju
Kim, Dong-Wan
Kim, Sang-We
Planchard, David
Ohe, Yuichiro
Felip, Enriqueta
Watkins, Claire
Cantarini, Mireiille
Ghiorghiu, Serban
Ranson, Malcolm
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[5] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[6] Asan Med Ctr, Seoul, South Korea
[7] Gustave Roussy, Villejuif, France
[8] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[9] Vall dHebron Univ Hosp, Barcelona, Spain
[10] AstraZeneca, Macclesfield, Cheshire, England
[11] Univ Manchester, Christie Hosp, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.8009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8009
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer
    Jiang, Tao
    Zhou, Caicun
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 370 - 372
  • [2] AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    Kim, Dong-Wan
    Planchard, David
    Ohe, Yuichiro
    Ramalingam, Suresh S.
    Ahn, Myung-Ju
    Kim, Sang-We
    Su, Wu-Chou
    Horn, Leora
    Haggstrom, Daniel
    Felip, Enriqueta
    Kim, Joo-Hang
    Frewer, Paul
    Cantarini, Mireille
    Brown, Kathryn H.
    Dickinson, Paul A.
    Ghiorghiu, Serban
    Ranson, Malcolm
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18): : 1689 - 1699
  • [3] AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.
    Ramalingam, Suresh S.
    Yang, James Chih-Hsin
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Rukazenkov, Yuri
    Frewer, Paul
    Cantarini, Mireille
    Ghiorghiu, Serban
    Janne, Pasi A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients
    Remon, Jordi
    Planchard, David
    [J]. FUTURE ONCOLOGY, 2015, 11 (22) : 3069 - 3081
  • [5] Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
    Zhang, Xiao-Yu
    Zhang, Yun-Kai
    Wang, Yi-Jun
    Gupta, Pranav
    Zeng, Leli
    Xu, Megan
    Wang, Xiu-Qi
    Yang, Dong-Hua
    Chen, Zhe-Sheng
    [J]. MOLECULES, 2016, 21 (09)
  • [6] Osimertinib (AZD9291), a mutant-selective EGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells
    Zhang, Xiao-Yu
    Lei, Zi-Ning
    Zhang, Yun-Kai
    Wang, Yi-Jun
    Gupta, Pranav
    Zeng, Leli
    Xu, Megan
    Wang, Xiu-Qi
    Yang, Dong-Hua
    Chen, Zhe-Sheng
    [J]. CANCER RESEARCH, 2017, 77
  • [7] Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
    Eberlein, Catherine A.
    Stetson, Daniel
    Markovets, Aleksandra A.
    Al-Kadhimi, Katherine J.
    Lai, Zhongwu
    Fisher, Paul R.
    Meador, Catherine B.
    Spitzler, Paula
    Ichihara, Eiki
    Ross, Sarah J.
    Ahdesmaki, Miika J.
    Ahmed, Ambar
    Ratcliffe, Laura E.
    O'Brien, Elizabeth L. Christey
    Barnes, Claire H.
    Brown, Henry
    Smith, Paul D.
    Dry, Jonathan R.
    Beran, Garry
    Thress, Kenneth S.
    Dougherty, Brian
    Pao, William
    Cross, Darren A. E.
    [J]. CANCER RESEARCH, 2015, 75 (12) : 2489 - 2500
  • [8] AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
    Ahn, M. J.
    Tsai, C. M.
    Yang, J. C. H.
    Shepherd, F. A.
    Satouchi, M.
    Kim, D. W.
    Bazhenova, L.
    Hirashima, T.
    Rukazenkov, Y.
    Cantarini, M.
    Mann, H.
    Ramalingam, S. S.
    Mitsudomi, T.
    Jaenne, P. A.
    Goss, G. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S625 - S626
  • [9] High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
    Nanjo, Shigeki
    Ebi, Hiromichi
    Arai, Sachiko
    Takeuchi, Shinji
    Yamada, Tadaaki
    Mochizuki, Satsuki
    Okada, Yasunori
    Nakada, Mitsutoshi
    Murakami, Takashi
    Yano, Seiji
    [J]. ONCOTARGET, 2016, 7 (04) : 3847 - 3856
  • [10] Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial–mesenchymal transition phenotype
    Jing Xu
    Xiaoting Zhao
    Dengfeng He
    Jinghui Wang
    Weiying Li
    Yinghui Liu
    Li Ma
    Mei Jiang
    Yu Teng
    Ziyu Wang
    Meng Gu
    Jianbin Wu
    Yue Wang
    Wentao Yue
    Shucai Zhang
    [J]. Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1413 - 1422
12345